New biomarker may predict response to PD-1 for melanoma; Academic team offers new tech for 'fixing' proteins;

> Investigators at the Mayo Clinic have flagged a new protein marker that may be predictive for patient response to PD-1 blockade immunotherapy for melanoma. An abstract of their findings was presented today at the American Association for Cancer Research International Cancer Immunotherapy Conference in New York City. Release

>  Researchers from Northwestern University and Yale University say they have developed a "user-friendly" technology that can help scientists fix "broken" proteins--a field that could have broad therapeutic implications. Release

> Three new studies flag metabotropic glutamate receptor 2 (mGluR2) as a new molecular target for the treatment of addiction. Release

Suggested Articles

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.

Dutch scientists used stem cells from CF patients to demonstrate a technique that corrects a mutation in the gene CFTR without having to cut DNA.

A new map of the thymus gland could help researchers understand how T cells develop and inspire treatments for cancer and autoimmune disease.